News Agency
The Times

Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

  • Written by PR Newswire
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

Approval follows U.S. FDA clearance of IND application for BCMA/CD19 dual-targeting FasTCAR-T GC012F

Company plans to initiate Phase 1/2 clinical trial in China in third quarter of 2023

SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Feb. 13, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global...

Read more: Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical...

How Does Temporary Fencing Help Simplify Project Planning?

Why Does Temporary Fencing Matter During Project Planning?  A controlled boundary is essential when construction, infrastructure maintenance, demolition,  landscaping, and other projects are underway. That is when temporary fencing becomes an important  option to consider. The fencing layout affects more than site... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion